Citius Oncology, Inc.

Citius Oncology Establishes Exclusive distribution agreement with Integris Pharma S.A for Southern European Access to Lymphir™ See link below: https://lnkd.in/eJ-m9GfK

Citius Oncology is pleased to announce a new distribution agreement with Cencora | Pharma solutions, as we continue to strengthen launch readiness for LYMPHIR™, our FDA‑approved immunotherapy for relapsed or refractory CTCL. This partnership marks another significant step towards broadening product access and reinforces our commitment to patients. Read the press release: https://lnkd.in/e8Ga2ysK #Oncology #Immunotherapy #CTLC #LYMPHIR

Citius Oncology prepares for the commercial launch of LYMPHIR™, an FDA-approved #immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (#CTCL). Final preparations are in process for a U.S. launch of LYMPHIR in the second half of 2025. Read the press release: https://lnkd.in/e9AWHJn6 #Oncology 

Citius Pharmaceuticals (Nasdaq: CTXR) is pleased to announce that its oncology-focused subsidiary Citius Oncology (Nasdaq: CTOR), has entered into a distribution services agreement with Cardinal Health (NYSE: CAH), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States. This agreement is designed to help provide access to LYMPHIR™ (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch. Read more in the press release: https://lnkd.in/e9qfnpsr #Pharma #Immunotherapy #Oncology #CTCL #Lymphoma

Citius Oncology’s (Nasdaq: CTOR) fiscal Q2 2025 financial results, visit the press release here: https://lnkd.in/e6CVnDaJ Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update. Read the press release here: https://lnkd.in/ex_skEbP

“ The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing clarity for coding and payment processing. This achievement is a key step in ensuring that LYMPHIR is accessible to patients with commercial and government insurance (VA, DoD, Medicare) coverage.” In case you missed it, dive into the press release: https://bit.ly/4aNeA70 #Healthcare #CTCL #OncNews #Oncology 

Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for #Medicare and #Medicaid Services. Read the press release here: https://bit.ly/4aNeA70   

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Key takeaways:  • 36.2% ORR • 1.4 month time to response • Median duration of response of 8.9 months • Tolerable safety profile In case you missed it, read more via American Society of Clinical Oncology (ASCO): https://lnkd.in/eQCytMZj #CTCL 

Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025. Read the press release here: https://lnkd.in/ePuG6Erx #Biopharma #CTCL

Citius Oncology has engaged Jefferies as our exclusive financial advisor to explore strategic alternatives. Read the press release here: https://lnkd.in/esAjrVsU